BMS Enters PD-L1/VEGF Bispecific Arena with $11.1B Deal for BNT327; Canbridge Founder Trust Sells HK$117M Stake

Amino Observation - Original Production by the Innovative Drug Team

Author | Huang Kai

Alphamab Oncology Controlling Shareholder Reduces Stake.

On June 3, Alphamab Oncology announced that one of its controlling shareholders, Rubymab Ltd., had entered into a placement agreement with an institution to transfer 14.6 million shares at a price of HKD 8.05 per share, amounting to HKD 117 million. All shares of Rubymab Ltd. are wholly owned by the Xu Ting Family Trust.

Facing the PD-L1/VEGF bispecific antibody craze, Bristol-Myers Squibb can't sit still.

On June 2, Bristol-Myers Squibb and BioNTech announced an agreement to co-develop and commercialize the PD-L1/VEGF bispecific antibody BNT327 globally. BMS will pay BioNTech an upfront payment of $1.5 billion and make non-contingent anniversary payments totaling $2 billion by 2028.

In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.

/ 01 /

Market Express

1) Hansoh Pharma Licenses GLP-1R/GIPR Agonist to Regeneron

On June 2, Hansoh Pharma announced that it had entered into a licensing agreement with Regeneron, granting the latter exclusive global rights (excluding mainland China, Hong Kong, and Macao) to develop, manufacture, and commercialize HS-20094, a GLP-1R/GIPR agonist.

/ 02 /

Capital Information

1) Alphamab Oncology's Actual Controller Reduces Holdings by HKD 1.17 Billion

On June 3, Alphamab Oncology announced that one of its controlling shareholders, Rubymab Ltd., had entered into a placement agreement with an institution to transfer 14.6 million shares at a price of HKD 8.05 per share, amounting to HKD 117 million. All shares of Rubymab Ltd. are wholly owned by the Xu Ting Family Trust.

/ 03 /

Pharmaceutical News

1) AstraZeneca's AZD0901 Receives Clinical Approval

On June 3, according to the CDE official website, AstraZeneca's AZD0901 received clinical approval and is planned to initiate research for the treatment of locally advanced resectable gastric esophageal adenocarcinoma in the perioperative setting.

2) Wuxi Zhikang Hongyi Biotechnology Co., Ltd.'s Injectable BC2027 Receives Clinical Approval

On June 3, according to the CDE website, Wuxi Zhikang Hongyi Biotechnology Co., Ltd.'s injectable BC2027 received clinical approval and is intended for the treatment of advanced solid tumors.

3) MacroMedics SVHRSP Injection Receives Clinical Approval

On June 3, according to the CDE official website, Wanjin Pharmaceutical's SVHRSP Injection received clinical approval and is intended for the rapid control of seizure clusters or status epilepticus.

4) Sanofi's Insulin Glargine and Lixisenatide Injection (II) Proposed for Priority Review

On June 3, according to the CDE official website, Sanofi's insulin glargine and lixisenatide injection (II) is proposed for priority review. It is applicable to adult patients with type 2 diabetes who have poor blood glucose control, in combination with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood glucose control.

5) Bowlin Pharmaceuticals BW-20507 Injection Granted Priority Review

On June 3, according to the CDE official website, Bowlin Pharmaceutical's BW-20507 injection is proposed for priority review for the treatment of chronic hepatitis B virus infection.

6) Disitamab vedotin as first-line treatment for advanced gastric cancer achieves comprehensive breakthrough in efficacy

On June 2, Rongchang Biotech announced at ASCO the results of a study on the use of Vedotin combined with Toripalimab (PD-1) and chemotherapy/trastuzumab as a first-line treatment for HER2-expressing locally advanced or metastatic gastric cancer. The study covered patients with high, medium, and low HER2 expression, significantly improving the efficacy of first-line treatment for advanced gastric cancer compared to the standard treatment in the control group, and extending the benefiting population to those who were previously unresponsive to targeted drugs.

7) Zai Lab Announces Latest Clinical Data for DLL3 ADC

On June 2, Zai Lab announced the latest Phase 1 study data of DLL3 ADC drug ZL-1310 at ASCO, showing robust anti-tumor activity, including intracranial responses.

8) Innovent Biologics CLDN18.2 ADC Latest Clinical Data Released

On June 3, Innovent Biologics orally presented at ASCO an update on the Phase I clinical study data of CLDN18.2 ADC drug IBI343 for the treatment of advanced pancreatic cancer. As of the data cutoff date, among the 44 subjects in the 6mg/kg dose group with CLDN18.2 1+2+3+≥60%, the confirmed objective response rate (cORR) was 22.7%, the disease control rate (DCR) was 81.8%, the median PFS was 5.4 months, and the median OS was 9.1 months.

/ 04 /

Overseas Pharmaceutical News

1) Bristol-Myers Squibb Collaborates with BioNTech to Develop PD-L1/VEGF Bispecific Antibody

On June 2, Bristol-Myers Squibb and BioNTech announced an agreement to jointly develop and commercialize the PD-L1/VEGF bispecific antibody BNT327 worldwide. BMS will pay BioNTech an upfront payment of $1.5 billion and non-contingent anniversary payments totaling $2 billion by 2028.

PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.